WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY) Read More
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED ACCESS PROTOCOL FOR IMETELSTAT Read More
WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY) Read More
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED ACCESS PROTOCOL FOR IMETELSTAT Read More
WEP CLINICAL PARTNERS WITH KINIKSA TO LAUNCH ARCALYST NAMED PATIENT PROGRAM Read More 17th August 2021
WEP CLINICAL EXECUTES MASTER SERVICES AGREEMENT WITH MEDLAB TO BRING NANABIS™ AND NANOCBD™ TO PATIENTS IN UK AND EUROPE VIA ETHICAL NAMED PATIENT PROGRAMMES Read More 19th July 2021
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS PLC TO LAUNCH NAMED PATIENT USE PROGRAM FOR TEPEZZA® (TEPROTUMUMAB-TRBW) Read More 18th May 2021
WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS Read More 25th March 2021
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB® Read More 1st March 2021
WEP CLINICAL PARTNERS WITH US BIOTECH COMPANY FOR THE NAMED PATIENT SUPPLY OF CANCER PRODUCT IN EX-US COUNTRIES Read More 24th August 2020
WEP CLINICAL PARTNERS WITH BTG SPECIALTY PHARMACEUTICALS FOR EUROPEAN SUPPLY OF VORAXAZE® Read More 1st July 2020